Meanwhile, using an inducible system in vivo, we showed that GABP reduction combined with temozolomide, a standard of care for patients with GBM, decreased cellular proliferation and dramatically prolonged survival of mice bearing MGMT methylated GBM, highlighting the therapeutic potential of targeting the GABP-TERT axis (Amen et al., 2021). The gene discussed is TERT; the disease is glioblastoma.